Search research articles
Contact Us
Filters
Showing results (181-190 of 194) with videos related to
Page
of 20
Sort By:
Journal for Immunotherapy of Cancer
|
December 22, 2021
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Yunpeng Yang, Ting Zhou, Xiaozhong Chen, et al.
Nature Medicine
|
November 5, 2021
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu, Qingyuan Zhang, Pin Zhang, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
JAMA
|
September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo, Jin Lu, Yuxian Bai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2021
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Shengxiang Ren, Jianhua Chen, Xingxiang Xu, et al.
The Lancet. Oncology
|
February 14, 2021
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Binghe Xu, Min Yan, Fei Ma, et al.
Molecular Cancer
|
January 4, 2022
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
Tao Jiang, Jianhua Chen, Xingxiang Xu, et al.
The Lancet. Oncology
|
June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
The Lancet. Respiratory Medicine
|
December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 194) with videos related to
Sort By:
Page
of 20
Journal for Immunotherapy of Cancer
|
December 22, 2021
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Yunpeng Yang, Ting Zhou, Xiaozhong Chen, et al.
Nature Medicine
|
November 5, 2021
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu, Qingyuan Zhang, Pin Zhang, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
JAMA
|
September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo, Jin Lu, Yuxian Bai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2021
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Shengxiang Ren, Jianhua Chen, Xingxiang Xu, et al.
The Lancet. Oncology
|
February 14, 2021
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Binghe Xu, Min Yan, Fei Ma, et al.
Molecular Cancer
|
January 4, 2022
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
Tao Jiang, Jianhua Chen, Xingxiang Xu, et al.
The Lancet. Oncology
|
June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
The Lancet. Respiratory Medicine
|
December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Page
of 20